+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 17 Actively Recruiting clinical trials

L

Actively Recruiting

Researchers are evaluating the long-term safety and effectiveness of abrocitinib oral suspension, with or without topical medications, in children aged 2 years and older who have moderate-to-severe atopic dermatitis. This Phase 3 open-label study includes two groups children who previously completed abrocitinib studies and those who have never participated in such studies. The study aims to better understand the treatments impact over an extended period. Participants will receive abrocitinib oral suspension throughout the study, which may last up to 24 months or until the medicine becomes commercially available, whichever happens first. The study will enroll up to 500 children globally, split between those continuing from previous trials and new participants aged 6 to under 12 years. All children will receive the same study treatment during this period. Throughout the study, participants will be closely monitored with regular assessments of safety, including treatment-related side effects and laboratory tests. Researchers will also evaluate skin condition improvements using various scales and indexes, itch intensity, quality of life measures, and the need for additional topical treatments. This comprehensive follow-up will last up to two years to track long-term effects and safety outcomes.

Age: 2Years - 11YearsAll GendersPhase 3
39 locations
I

Actively Recruiting

Researchers are studying abrocitinib to see if it improves eczema symptoms and is safe for children aged 6 to less than 12 years who have moderate-to-severe eczema. The study is a phase 3, randomized, double-blind, placebo-controlled trial that compares abrocitinib with a placebo. Participants will be randomly assigned to receive either the test medicine or placebo for 16 weeks, with the entire study lasting about 24 weeks. Participants will receive abrocitinib or placebo as a liquid oral suspension. They will use an electronic diary, similar to a cell phone, to record questionnaire responses and receive daily reminders to take the medication and complete questionnaires. They will also wear a wrist device resembling a childrens watch to monitor scratching caused by their eczema. The study involves regular clinic visits, laboratory tests, physical exams, and vital sign monitoring to assess health and treatment effects. During the study, researchers will assess eczema severity using validated scales such as the Investigators Global Assessment and the Eczema Area and Severity Index at week 12. They will also monitor itch severity and improvement through a numerical rating scale at weeks 2 and 12. Health checks including height, weight, temperature, blood pressure, and heart rate will be performed. Participants will have scheduled visits and phone calls with study staff to track progress and safety throughout the study period.

Age: 6Years - 11YearsAll GendersPhase 3
47 locations
A

Actively Recruiting

Researchers are evaluating the effects of AZD6793 in adults with moderate to very severe chronic obstructive pulmonary disease COPD. This Phase IIb study compares two different doses of AZD6793 to placebo tablets to assess their efficacy and safety. The study is randomized, double-blind, placebo-controlled, and involves about 970 participants worldwide. Participants will be randomly assigned to one of three groups two different doses of AZD6793 or a matching placebo. The study lasts for 24 weeks, during which participants will take oral tablets of their assigned treatment. The trial aims to measure how well AZD6793 works to reduce COPD exacerbations compared to placebo. Throughout the study, participants will have regular assessments including lung function tests, symptom questionnaires, and blood tests to measure drug levels. Researchers will monitor the rate of COPD exacerbations, lung function changes, and symptom scores over 24 weeks. Safety and tolerability of the treatments will also be closely observed during this period.

Age: 40Years +All GendersPhase 2
367 locations
U

Actively Recruiting

Healthy Volunteer

Researchers are evaluating the Methinks Stroke Suite, an AI-based imaging software, to see if it can help speed up the transfer of acute stroke patients who may need thrombectomy from local stroke centers to specialized centers. The study focuses on patients initially assessed at centers that cannot perform endovascular therapy EVT. The main goals are to find out whether the software reduces the time to decide on patient transfer and how accurately it identifies candidates for EVT. The study compares patient care after integrating Methinks Stroke Suite into the stroke workflow with a historical group treated before its use. Patients will have a CT scan analyzed by the AI software at the local center. If the software and clinical judgment suggest thrombectomy might be needed, patients are transferred to specialized centers. If no large vessel occlusion is detected, further imaging like CT angiography may be done to reassess. This is an open-label, quasi-experimental study conducted across multiple centers in Catalonia, Spain. Participants will undergo CT scans at their local stroke center, with imaging data processed by the Methinks software. They will be followed for 90 days after their stroke to assess recovery and functional outcomes. Researchers will measure time from arrival to transfer decision, evaluate the softwares accuracy in detecting large vessel occlusions, monitor treatment rates, and gather clinician feedback on using the software. Safety during patient transfers will also be tracked. The study plans to enroll about 250 patients and includes a follow-up period of 3 months after stroke.

Age: 18Years +All Genders
2 locations
E

Actively Recruiting

Healthcare-associated infections, including surgical site infections SSI, are a major concern for patient safety and healthcare systems worldwide. Surveillance is a key component recommended by the World Health Organization to prevent these infections. This research aims to evaluate a new artificial intelligence algorithm designed to detect SSIs in patients who have undergone elective colorectal surgery, comparing it to traditional manual surveillance methods within a national infection surveillance program. The study compares two groups of patients undergoing colorectal surgery one monitored using the standard manual method for identifying SSIs, and the other assessed with a novel AI algorithm. This algorithm analyzes clinical data such as clinical notes, microbiology reports, and coding for diagnoses and complications to identify suspected infections at three different anatomical levels. The surveillance covers up to 30 days after surgery to detect infections occurring after hospital discharge. Participants will be followed up with continuous monitoring to detect surgical site infections within the 30-day post-operative period. Researchers will assess the rate of SSIs detected by both the manual method and the AI algorithm. The study uses data routinely collected during postoperative care, focusing on how well the AI system identifies infections compared to current practices. The study is observational and does not involve treatment interventions, and participation duration depends on the postoperative surveillance period.

Age: 18Years +All Genders
1 location
C

Actively Recruiting

Researchers are studying breast cancer patients who have a positive sentinel lymph node after receiving neoadjuvant systemic treatment. The trial evaluates whether axillary radiotherapy ART reduces the risk of lymphedema compared to axillary lymph node dissection ALND in these patients. The study also examines recurrence and overall survival rates, as well as quality of life. This is a prospective, randomized, open-label, parallel group, multicenter study involving approximately 820 patients over 5 years. Participants are divided into two groups one receives axillary radiotherapy without lymphadenectomy, including radiation to levels I and II axilla, level III, supraclavicular area, and possibly the internal mammary chain the other group undergoes axillary lymph node dissection plus radiotherapy to level III, supraclavicular area, and possibly the internal mammary chain. Patients are stratified by neoadjuvant treatment type chemotherapy or hormone therapy. A pilot phase with the first 200 patients has been completed, and interim analysis will be performed. During the study, participants undergo evaluations including imaging by ultrasound or MRI to assess axillary response after neoadjuvant therapy. Researchers will track disease-free survival up to 5 years, overall survival up to 5 years, and incidence of lymphedema up to 3 years after surgery. Quality of life and safety outcomes will also be monitored. The study aims to provide data on whether avoiding lymphadenectomy is a viable option for patients responding well to neoadjuvant treatment.

Age: 18Years +All GendersPhase Not Applicable
61 locations
R

Actively Recruiting

Researchers are evaluating the effects of Nintedanib Solution for Inhalation AP02 on lung function and fibrosis in adults with idiopathic pulmonary fibrosis IPF. This phase 2 study aims to assess the safety, tolerability, and efficacy of AP02 by comparing two different doses to a placebo in participants 40 years or older with IPF who are either untreated or have stopped certain IPF medications for at least 3 months. Participants will be randomly assigned to one of three groups to receive either a low dose, high dose of AP02, or placebo solution via inhalation using a nebulizer twice daily for 12 weeks. The study includes a 16-week period during which participants will attend six office visits and receive one phone call for ongoing assessments and monitoring. Throughout the trial, lung function will be measured with breathing tests, and participants will complete health questionnaires. Researchers will monitor lung fibrosis through imaging scores and track disease progression over 12 weeks. Safety and health will be regularly checked by doctors during visits, ensuring careful observation of participants well-being during the study.

Age: 40Years +All GendersPhase 2
49 locations
A

Actively Recruiting

This research aims to evaluate how well ChatGPT-4 can detect surgical site infections SSI at three anatomical levels using electronic health records from patients who have had colorectal surgery. Surgical site infections are a common healthcare-associated infection that affects patient health and healthcare systems. Current surveillance methods are manual and time-consuming, and this study explores using artificial intelligence to improve detection accuracy. The study compares two methods of SSI detection for patients undergoing elective colorectal surgery the standard manual surveillance performed by infection control teams and an automated approach using OpenAIs ChatGPT-4 chatbot trained with CDC criteria. The comparison is retrospective, using data from a nationwide infection surveillance program as the gold standard. Participants surgical records and infection status will be analyzed to measure the rate of surgical site infections within 30 days after surgery. The study involves reviewing clinical course texts, microbiology reports, and diagnostic codes to assess AIs accuracy. The evaluation focuses on how well ChatGPT-4 identifies SSIs compared to manual methods, aiming to inform future surveillance improvements.

Age: 18Years +All Genders
1 location
C

Actively Recruiting

Researchers are collecting detailed information about patients with venous thromboembolism VTE to improve understanding of this condition, especially in groups often excluded from clinical trials such as pregnant women, elderly patients, and those with severe health issues. This observational registry aims to provide data that can help reduce death rates, recurrences of blood clots, bleeding problems, and arterial events related to VTE. This study gathers clinical details about each patient, including other health conditions, and tracks the type, dose, duration, and results of antithrombotic treatments over the first three months. The registry is accessible online to assist doctors in managing complex cases by comparing patient profiles and identifying those at higher risk of complications. Participants clinical status and treatment outcomes are recorded, focusing on recurrence of VTE, bleeding events, and mortality over a three-year period. The information supports the creation of predictive scores to help healthcare providers identify patients at higher risk. The study started in 2001 and plans to continue until 2027, with ongoing data collection and follow-up.

All AgesAll Genders
305 locations
E

Actively Recruiting

Researchers are studying adults with fibrosing interstitial lung disease ILD, excluding idiopathic pulmonary fibrosis IPF, who have been diagnosed within the last three years and may be at risk of developing progressive pulmonary fibrosis PPF. The trial aims to evaluate the effects of a medicine called nerandomilast in slowing lung function decline and disease progression in this group. Participants are randomly assigned to one of two groups one takes nerandomilast tablets, and the other takes placebo tablets that look identical but contain no medicine. The study lasts up to about 2 years and 4 months, during which participants take their assigned tablets regularly and undergo scheduled assessments to monitor their lung condition. Throughout the study, participants visit the study site regularly for tests including spirometry to measure forced vital capacity FVC and diffusing capacity of the lungs for carbon monoxide DLCO. High-resolution computed tomography HRCT scans track lung changes over time. Researchers compare these results between groups to assess treatment effects, while monitoring overall health and any side effects.

Age: 18Years +All GendersPhase 3
162 locations

1-10 of 17

1